| Serial Number | 98211995 |
| Word Mark | ERUDITE |
| Filing Date | Friday, October 6, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, August 20, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 25, 2024 |
| Goods and Services | Providing medical information; providing medical information relating to therapies and treatments for cognitive impairment associated with schizophrenia and mental illness and disorders |
| Goods and Services | Pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical preparations; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations and evaluating epidemiological results; pharmaceutical research and development services in the field of cognitive impairment associated with schizophrenia and mental illness and disorders; conducting clinical trials for others for pharmaceutical preparations for the treatment and prevention of cognitive impairment associated with schizophrenia and mental illness and disorders; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations for the treatment and prevention of cognitive impairment associated with schizophrenia and mental illness and disorders, and evaluating epidemiological results for treatments for cognitive impairment associated with schizophrenia and mental illness and disorders; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials pertaining to therapies and treatments for cognitive impairment associated with schizophrenia and mental illness and disorders |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, October 14, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, October 14, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Neurocrine Biosciences, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Party Name | Neurocrine Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Event Date | Event Description |
| Tuesday, October 10, 2023 | NEW APPLICATION ENTERED |
| Wednesday, May 15, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, May 21, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, June 5, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 25, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, June 25, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 20, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Saturday, October 14, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |